Advertisement

Covaxin gets approval for emergency use for children aged 2-18 years

In a statement, meanwhile, Bharat Biotech said that this represents one of the first approvals worldwide for COVID-19 vaccines for the 2-18 age group.

Covaxin gets approval for emergency use for children aged 2-18 years
SHARES

According to reports, the Subject Expert Committee (SEC) of the drug regulator has recommended granting an emergency use authorisation to Bharat Biotech's Covaxin for children aged between 2-18.

Moreover, the SEC has submitted its recommendation to the Drugs Controller General of India (DCGI) for final approval. Last week, Bharat Biotech had submitted Phase 2/3 clinical trials data of children's trials to the DCGI for its verification and subsequent approval for emergency use authorisation (EUA) for the jab.

In a statement, meanwhile, Bharat Biotech said that this represents one of the first approvals worldwide for COVID-19 vaccines for the 2-18 age group.

On the other hand, earlier on Tuesday, September 21, Krishna Ella, managing director of the Hyderabad-based pharmaceutical company, told the reporters that Bharat Biotech has completed its Phase 2/3 trials of COVID-19 vaccine, Covaxin, on children below 18 years of age.

While addressing the media, he said that the production of Covaxin would touch 55 million doses in October. The output of Covaxin was 35 million in September. He also mentioned that the number of volunteers is touching 1000 and data analysis is still ongoing. He would submit the data to the regulator by next week.

ALSO READ: Coronavirus Vaccination: Here's the list of Centres administering both doses of Covishield and Covaxin    

Read this story in मराठी
RELATED TOPICS
Advertisement
MumbaiLive would like to send you latest news updates